LLY and AMGN Related Headlines
Go Back- Roche obesity drug shows 15.5% weight loss in diabetes trial
- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- The Next Generation of the GLP-1 Revolution Is Already Underway
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Barclays launches U.S. biopharma coverage with four preferred picks
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Here's the list of top biotech stocks to own for 2026
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
LLY and AMGN Related Press Releases
Go Back- The Next Generation of the GLP-1 Revolution Is Already Underway
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
